It’s been nearly a decade since the first CAR-T cancer cell therapy was approved by the FDA, offering a powerful and durable therapy against tumours. But when it comes to fighting solid tumours, CAR ...
Boehringer Ingelheim has partnered with New York-based Envisagenics to hunt for new targets in hard-to-treat solid tumors, opening up more than $1 billion (€873 million) in potential payments.
London-based Big Picture Bio has launched with £2.2 million (€2.6 million) in funding to build an AI platform that designs drug combinations for cancer, starting largely with medicines that are ...
Novartis has licensed an undisclosed preclinical radioligand therapy from China’s BoomRay Pharmaceuticals in a deal worth up to $900 million (€786 million), adding another asset to one of the pharma ...
Belgian biotech Remynd has secured a €3.5 million investment from the Alzheimer’s Drug Discovery Foundation (ADDF) to move ...
UK biotech Mestag Therapeutics has raised $40 million and appointed veteran drug developers Lindsey Rolfe as chief medical officer and Pascal Merchiers as chief development officer, as the company ...
For BioNTech, 2026 could become one of the most decisive years since its pandemic-driven breakthrough. The pipeline is broad, the coffers are well stocked, partnerships are numerous, and the outlook ...
The European Investment Fund has launched a new fund of funds with a target volume of €15 billion to strengthen growth financing in Europe’s technology sector. The programme is considered the largest ...
New data from the World Conference on Lung Cancer in Seoul are giving BioNTech’s oncology strategy more substance beyond its ...
Beacon Therapeutics' gene therapy laru-zova met its U.S. pivotal endpoint in X-linked retinitis pigmentosa, while results on the trial's separately designated European primary efficacy measure were ...
Australian radiopharma company Telix Pharmaceuticals has agreed to acquire Munich-based ITM Isotope Technologies for an ...
Novartis has stopped developing its TREM2 antibody VHB937 (lifonebart) in amyotrophic lateral sclerosis (ALS) after the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results